1. Introduction {#sec1}
===============

Atherosclerosis can be defined as an inflammatory process: the exposure of extracellular matrix proteoglycans facilitates the subendothelial accumulation of low-density lipoprotein (LDL) which is then exposed to oxidation. Oxidized LDL (oxLDL) activates endothelial cells and stimulates them to secrete chemokines and express adhesion molecules which lead to the extravasation of different immune cells, such as monocytes and T cells. After migration into the intima, monocytes differentiate into macrophages which take up oxidized lipids and thereby transform into foam cells. The growing accumulation of cell debris and lipids leads to the formation of a necrotic plaque core. Smooth muscle cells migrate from the media into the intima where they produce extracellular matrix (ECM) proteins which compose a fibrous cap covering the plaque core, thereby stabilizing the atheroma (plaque stabilization). Macrophages lead to the thinning of this fibrous cap through the release of matrix metalloproteinases which is the prerequisite of plaque rupture (plaque destabilization). Plaque rupture is followed by acute ischemic events such as stroke or acute myocardial infarction. However, the reason for inflammation in atherosclerosis was unknown for a long time. In recent times, it has been unraveled that certain autoantigens like oxLDL might be the trigger for chronic inflammation in atherosclerosis. Autoantigens are presented in atherosclerotic lesions by antigen-presenting cells (APC) like macrophages or DCs and recognized by T cells. T cells in turn contribute to the inflammatory state through the secretion of different proinflammatory mediators \[[@B1]\].

It has been shown that DCs as professional APCs are present in atherosclerotic lesions and that they are essential for the initiation of an autoimmune process through activation of T cells. There are two major subpopulations of DCs: myeloid DCs (mDCs) and plasmacytoid DCs (pDCs). mDCs mainly recognize bacterial fragments and oxidized autoantigens, and pDCs are specialized in sensing viral fragments. Autoantigens like oxLDL promote the maturation of DCs, enabling them to trigger an antigen-specific T cell activation. IFN-*α*, secreted by pDCs, correlates with plaque instability and stimulates naïve CD4+ T cells to differentiate into cytotoxic T cells and express IFN-*γ*, a potent regulator of T cell function \[[@B2]\]. In bioengineered arteries, activated mDCs stimulate autologous CD4+ T cells to produce IFN-*γ*, infiltrate the vessel wall, and cause inflammation \[[@B3]\]. However, it has been shown recently that DCs are also able to induce antigen-specific tolerance in peripheral T cells, which is necessary to suppress the progression of atherosclerosis \[[@B4], [@B5]\].

Within the T cell subset, the majority of pathogenic cells in atherosclerotic lesions belong to the T helper (Th) 1 profile, producing proinflammatory mediators such as IFN-*γ*. The role of Th2 cells in atherogenesis remains controversial. There is now accumulating evidence that within the T cell population there is also a subset of specialized T cells with anti-inflammatory properties: regulatory T cells (Tregs). Tregs are known to play a critical role in the control of inflammation and autoimmunity including chronic vascular inflammation causing atherosclerosis. An increase in Tregs was shown to correlate with a reduction in atherosclerosis in animal models \[[@B6]\], and Tregs depletion promoted atherosclerosis in mouse models \[[@B7]\]. Naturally occurring Tregs produce IL-10 and TGF-*β*. These cytokines were shown to be protective regarding plaque development \[[@B8]\].

A theory gaining more and more acceptance trying to explain the reason for atherogenesis is the imbalance between immune cells producing proatherogenic mediators and regulatory T cells with immunosuppressive, anti-atherogenic properties.

The aim of our study was to answer the following questions: (1) whether the presence of certain immune cells is associated with the presence of other pro- or anti-inflammatory cells, for example, myeloid or plasmacytoid DCs with proinflammatory T cells or anti-inflammatory Tregs, and (2) whether the expression of functional molecules such as HLA-DR, CD25, and different chemokine receptors which might be involved in the attraction of circulating immune cells correlates with the plaque stability.

2. Methods {#sec2}
==========

2.1. Patients {#sec2.1}
-------------

Plaque specimens of 29 patients undergoing endarterectomy of elastic arteries were analyzed in our present study. Indications for carotid endarterectomy (*n* = 17) were based on NASCET and ACAS criteria \[[@B9], [@B10]\]. Indications for femoral endarterectomies (*n* = 12) were high grade stenoses \< 3--10 cm length causing relevant reductions in the walking distance \[[@B11]\]. Duplex scanning, magnetic resonance imaging, or angiography was performed to quantify the degree of stenosis prior to surgery. The study was approved by the local ethics committee and conducted in concordance with the Declaration of Helsinki. All patients gave informed written consent. Clinical data are listed in [Table 1](#tab1){ref-type="table"}.

As controls, 12 vessel specimens of elastic arteries were obtained from accident or suicide victims who did not show any macroscopic or histological signs of atherosclerosis.

2.2. Histological Analysis {#sec2.2}
--------------------------

Endarterectomy specimens were fixed in 4% formalin. Areas with extensive plaque formation were cut out for further analyses. Sections with total vessel occlusion were excluded from the study. Plaques used in this study were at an advanced stage (types IV to VI) according to the AHA classification \[[@B12]\]. After decalcification in EDTA for 4 weeks, plaques were paraffin-embedded. Serial sections (4 *μ*m) were cut and mounted on glass slides. Trichrome staining was performed to analyze plaque morphology and plaque regions as previously described \[[@B13]\] ([Figure 1](#fig1){ref-type="fig"}). The fibrous cap was defined as the area between the lipid core and the lumen. The lipid core was defined as the inner, in unstable plaques lipid-rich and necrotic part. The plaque shoulders were located where the fibrous cap hits the regular vessel wall at an angle of approximately 90°. Media was considered the fibrous area surrounding the lipid core. All specimens were analyzed blinded to the clinical symptoms and the identity of each patient. The sizes of the lipid core area (mm^2^) and of the total plaque area (mm^2^) were measured by computer aided planimetry (Image J 1.43u, Wayne Rasband, NIH, USA). The lipid core ratio (LCR, %) was calculated (lipid core area/plaque area × 100). The fibrous cap was measured at its narrowest site. According to histological criteria \[[@B14]\], plaque specimens were histologically classified as stable, fibrous lesions (fibrous cap \> 100 *μ*m, LCR \< 40%, ≤ 3 neovessels/0.2 mm^2^), or unstable, vulnerable, lipid-rich plaques (fibrous cap \< 100 *μ*m, LCR \> 40%, neovascularization, \>3 neovessels/0.2 mm^2^) ([Table 2](#tab2){ref-type="table"}).

2.3. Immunohistochemical Stainings {#sec2.3}
----------------------------------

The antibodies used for immunohistochemical staining are listed in [Table 3](#tab3){ref-type="table"}, and catalyzed signal amplification technique (CSA System, DakoCytomation, Hamburg, Germany) was used according to manufacturer\'s instructions. CD34 immunostaining helped to detect neovascularization as a criterion for plaque instability \[[@B15]\]. The sections were treated with irrelevant isotype-matched antibodies as appropriate negative controls.

2.4. Quantification of Immunostained Cells {#sec2.4}
------------------------------------------

Digital images of different plaque regions (magnification 200x) were taken with a CCD-camera (Zeiss AxioCam HRC, Jena, Germany). Cells were digitally counted in defined random areas (0.1 mm^2^) in each plaque region using a digital image processing software (Axiovision, Zeiss, Jena, Germany). For each quantification, the color threshold for immunostained cells was manually adjusted until the computerized detection matched the visual interpretation. The mean cell number per plaque was calculated from the cell numbers assessed in the different plaque regions. The results showed an intra- and interobserver variability of less than 10%.

2.5. Statistical Analysis {#sec2.5}
-------------------------

Statistical analysis was performed with SigmaPlot Software Version 12.0 (Systat Software Inc.). All values are reported as median; *P* \< 0.05 was considered statistically significant. The nonparametric Mann-Whitney Rank Sum Test was used to compare the number of different cells between the different study groups. Correlation analyses were performed using Spearman Rank Order Test.

3. Results {#sec3}
==========

In this study, the cellular composition of 29 advanced plaques that were classified as stable or unstable according to established criteria was immunohistochemically analyzed. After immunohistochemical staining, the frequencies of different immune cells as well as functional markers were compared between unstable plaques (*n* = 15), stable plaques (*n* = 14), and vessels without any signs of atherosclerosis that served as control (*n* = 12). For absolute cell numbers and *P* values see [Table 4](#tab4){ref-type="table"}.

3.1. Emergence of DCs in Stable and Unstable Atherosclerotic Lesions {#sec3.1}
--------------------------------------------------------------------

Macrophages (CD68+) as typical and well-known APCs were significantly more often present in advanced atherosclerotic lesions than in healthy vessels ([Table 4](#tab4){ref-type="table"}). To investigate the frequency of dendritic cells (DCs) as other important APCs in atherosclerosis, immunostaining of plaques with different DC markers was performed ([Table 4](#tab4){ref-type="table"}, [Figure 2](#fig2){ref-type="fig"}). To investigate the global emergence of myeloid (m) DCs, the expression of fascin and S100 was analyzed. The number of fascin+ mDCs was significantly higher in unstable than in stable plaques (1.6-fold) or control vessels (1.9-fold). The frequency of S100+ DCs was also significantly 1.6-fold higher in unstable than in stable plaques. This supports the theory of an increase in the number of mDCs in the course of plaque destabilization. To further investigate the maturation level of DCs during the process of plaque destabilization, immunohistochemical staining was performed with markers that allow the differentiation between mature mDCs (CD83) and immature mDCs (CD209). For mature mDCs, a higher emergence was visible in stable plaques compared to control vessels (1.6-fold), and a further significant increase was visible in emergence in unstable compared to stable lesions (5.9-fold). The significant increases in the cell number of immature mDCs in the course of plaque progression were lower than those of mature mDCs ([Table 4](#tab4){ref-type="table"}). On the contrary, for pDCs (CD123+, CD204+), no significant difference was detected between unstable and stable plaques.

In addition to the immunostaining with cellular markers, we also performed immunostaining with HLA-DR, a functional APC marker which is upregulated through activation. The frequency of HLA-DR expressing cells was significantly higher in unstable than in stable plaques (1.6-fold) and control vessels (2.4-fold).

3.2. Frequency of T Cells in Different Stages of Atherosclerotic Lesions {#sec3.2}
------------------------------------------------------------------------

### 3.2.1. Proinflammatory T Cells {#sec3.2.1}

The frequency of T cell subgroups was also compared for stable and unstable atherosclerotic plaques ([Table 4](#tab4){ref-type="table"}, [Figure 3](#fig3){ref-type="fig"}). The number of CD3+ T cells was significantly higher in unstable than in stable lesions (2.3-fold) or control vessels (4.5-fold). Also, CD4+ T helper cells and CD8+cytotoxic T cells occurred significantly more often in unstable than in stable lesions (3.4-fold). Furthermore, the emergence of natural killer T cells as another T cell subset playing an important role in atherosclerosis was investigated by immunostaining with CD161. A significantly higher emergence of these cells in unstable than stable lesions (1.5-fold) or healthy vessels (6.3-fold) was observed.

### 3.2.2. Activated T Cells {#sec3.2.2}

CD25 is expressed by activated B and T cells, including Tregs. The CD25 expression was investigated in advanced lesions comparing unstable and stable plaques. The number of CD25+ T cells was significantly 6.6-fold higher in vulnerable than fibrous atherosclerotic lesions. As an early activation marker which is also expressed by activated B and T cells as well as macrophages and platelets, occurrence of CD69 was investigated. There was a significant 1.7-fold higher number of CD69+ cells in unstable than stable plaques ([Table 4](#tab4){ref-type="table"}).

### 3.2.3. Anti-Inflammatory T Cells {#sec3.2.3}

In contrast to the observations of higher cell numbers of DCs and proinflammatory T cells, the number of FoxP3+ Tregs was significantly lower in vulnerable than in stable plaques (3.5-fold decrease) ([Table 4](#tab4){ref-type="table"}, [Figure 4](#fig4){ref-type="fig"}).

3.3. Expression of Chemokine Receptors in Advanced Plaques {#sec3.3}
----------------------------------------------------------

In addition to certain surface molecules of different immune cells, the expression of different chemokine receptors was investigated to analyze the role of chemoattraction during atherogenesis. CCR6 is expressed on immature DCs. A significantly higher 2.1-fold number of CCR6+ cells was observed in unstable compared to stable lesions or control vessels. CCR4 is expressed on DCs and T and B cells. The emergence of CCR4+ cells was significantly higher in vulnerable than fibrous lesions (2.1-fold) or control vessels (2.7-fold). This demonstrates a potential role of chemokine receptors in the recruitment of proinflammatory cells aggravating vascular inflammation.

3.4. Correlation Analyses of Proinflammatory and Anti-Inflammatory Cells {#sec3.4}
------------------------------------------------------------------------

Several significant correlations between different proinflammatory cells were observed in advanced plaques, for example, correlations between different subtypes of T cells and subsets of DCs ([Table 5](#tab5){ref-type="table"}). However, there were also many significant correlations between T cell subsets and mDCs, for example, fascin+DCs-CD4+ cells, fascin+DCs-CD161+ cells, CD209+DCs-CD8+ cells, and CD83+DCs-CD4 cells (correlation coefficients \[*r*-values\] \> 0.6, *P* values \< 0.001). This shows that several proinflammatory cells are equally attracted into the vessel wall during atherogenesis. Also, the functional marker of APC HLA-DR correlates with the marker of activation for T cells CD25 (*r* = 0.67, *P* \< 0.001), implicating that not only the attraction of these cells but also their activation significantly correlates in atherogenesis.

To investigate chemoattraction, the correlation between proinflammatory cells and chemokine receptors was investigated. There were significant correlations found for proinflammatory cells and chemokine receptors: CCR4+cells-CD3+cells (*r* = 0.56, *P* = 0.002), CCR4+cells-CD25+cells (*r* = 0.48, *P* = 0.01), CCR4+cells-CD4+cells (*r* = 0.45, *P* = 0.02), and CCR6+cells-CD8+cells (*r* = 0.46, *P* = 0.01). These positive correlations between chemokine receptors and different proinflammatory cells during plaque destabilization implicate a possible role of chemoattraction of these cells into the atherosclerotic plaque.

Contrary to the positive correlations between different subsets of proinflammatory cells, a significant inverse correlation was visible between anti-inflammatory FoxP3+ Tregs and proinflammatory cells such as CD4+ T-helper cells (*r* = −0.40, *P* = 0.03), CD83+ (*r* = −0.39, *P* = 0.04), and CD209+ (*r* = −0.43, *P* = 0.04) DCs as well as chemokine receptors such as CCR4 (*r* = −0.38, *P* \< 0.05) ([Figure 5](#fig5){ref-type="fig"}).

3.5. Correlation of the Emergence of Different Immune Cells with Clinical Data {#sec3.5}
------------------------------------------------------------------------------

There was no significant correlation between the frequency of the cells investigated and cardiovascular risk factors or ischemic symptoms (data not shown). Interestingly, a preexisting statin therapy might influence the frequency of immune cells in plaques. Statin-treated patients showed a trend to a more stable plaque morphology, a significantly decreased number of fascin+ and CD83+ DCs (2.1-fold decrease, *P* = 0.006; 3.6-fold decrease, *P* = 0.04), and a significantly higher emergence of FoxP3+ Tregs (2.6-fold increase, *P* = 0.04) ([Figure 6](#fig6){ref-type="fig"}). This decrease in proinflammatory cells and increase in cells with anti-inflammatory properties underline the plaque-stabilizing effects of statins ([Figure 7](#fig7){ref-type="fig"}).

3.6. Emergence of Certain Immune Cells in Different Regions of the Plaque {#sec3.6}
-------------------------------------------------------------------------

For T helper cells, plaque destabilization is attended by an increase of cells in the lipid core and the plaque shoulders as well as a reduction in the tunica media ([Figure 3](#fig3){ref-type="fig"}). This can be explained by the fact that oxidized lipid present in the lipid core is one of the major triggers attracting T cells into the vascular wall. As shown in [Figure 2](#fig2){ref-type="fig"}, the distribution of fascin+ DCs is almost equal in plaques with stable and unstable morphology. In unstable plaques, Tregs seem to be mainly in the lipid core. In rupture-prone shoulders there is a lower relative and absolute number of Tregs present in unstable lesions ([Figure 4](#fig4){ref-type="fig"}).

4. Discussion {#sec4}
=============

Atherosclerosis as an inflammatory disease of the vessel wall involves different types of immune cells. In a former study, Yilmaz et al. \[[@B13]\] showed that DCs as very potent APCs play an important role during plaque destabilization. There is also accumulating evidence that Tregs as anti-inflammatory, tolerance-inducing T cells are involved in atherogenesis \[[@B16]\]. Recently, DCs were shown to be able to induce antigen-specific tolerance in peripheral T cells \[[@B4], [@B5], [@B17]\]. This raises the question in which way DCs and T cells interact during atherogenesis, as inductor of pro- or anti-inflammatory T cells.

Therefore, the aim of the present study was to analyze the frequency of different immune cells in advanced plaques subdivided in stable und unstable lesions according to histological criteria \[[@B13]\] and investigate whether the presence of DCs is associated with the presence of pro or anti-inflammatory cells. Furthermore the expression of functional molecules and different chemokine receptors were analyzed to get insights in possible mechanisms of attraction. The following results were observed.

As expected, in unstable plaques we detected significantly higher numbers of mDCs, T cells, T helper cells, cytotoxic T cells, natural killer cells, and activated T cells compared to stable lesions. This shows that plaque destabilization is accompanied by an increase of proinflammatory cells as shown in former studies \[[@B18]\]. A recent study showed a coaccumulation of DCs and natural killer cells during plaque progression \[[@B19]\]. Within mDCs, mature DCs are able to cause an immune response through antigen-specific T cell activation, and immature DCs are thought to mediate tolerance \[[@B20], [@B21]\]. We were able to show a higher number of mature mDCs in unstable compared to stable atherosclerotic lesions which show an increase in vascular inflammation in the course of plaque progression. The equal number in the frequency of pDCs in stable and unstable plaques is not surprising. Former studies showed that pDCs are not recruited into inflammatory but rather lymphatic tissue \[[@B22], [@B23]\]. pDCs were formerly described to be present in atherosclerotic plaques and suggested to activate T cells \[[@B2]\]. However, apparently they do not seem to play a major role in atherogenesis \[[@B24]\].

Additionally, the emergency of Tregs as important anti-inflammatory cells was analyzed. There was a low number of Tregs present in control vessels and a significant 4.4-fold increase in Tregs frequency in stable plaques was obvious. An explanation might be that in healthy vessels only few inflammatory cells are present. Atherogenesis then goes along with recruitment of immune cells to the lesion site \[[@B25]\]. Then in the course of plaque destabilization a decrease in Treg frequency to less than a third was evident. This inverse correlation between Tregs and plaque rupture suggests an anti-inflammatory function of these cells in atherosclerosis.

Tregs can be divided into two entities: thymus-derived natural Tregs and peripherally generated induced Tregs. In our study, Tregs have been characterized by the marker FoxP3 which is expressed by both subgroups and thus does not allow us to differentiate between natural and induced Tregs. Recently, novel markers have been found that might help to characterize natural Tregs: natural Tregs have a higher expression of neuropilin 1 and Helios compared to induced Tregs \[[@B26]\]. In further experiments, these new markers should be investigated in IHC staining experiments to further analyze Tregs in atherosclerotic plaques and their role in atherogenesis.

So far, to our knowledge only three papers investigating the number of FoxP3+ Tregs have been published \[[@B27]--[@B29]\]. de Boer et al. \[[@B27]\] compared advanced lesions to early lesions and observed significantly increased numbers of Tregs in vulnerable, high risk compared to early lesions. There was no significant difference between vulnerable and fibrosclerotic lesions found. Patel et al. \[[@B28]\] observed higher numbers of Tregs in plaques from patients with ischemic symptoms than asymptomatic patients. Because of similar clinical data of the included patients, protocol differences of cell analyses might be a reason for the discrepancy of the results of these studies and our results. In the present study, five plaque regions were separately evaluated for each plaque, whereas de Boer et al. evaluated the emergence of Tregs only in the intima or adventitia. Patel et al. analyzed twenty fields per section, but it is not specifically mentioned which plaque regions the fields originated from. Recently, a study was published which revealed very similar results compared to our own investigations. Dietel et al. \[[@B29]\] showed decreased numbers of Tregs in unstable plaques and an inverse correlation with mDCs. For immunostaining, Dietel et al. used other DC markers (CD11c and DC-LAMP) compared to our study, showing that the results are independent of a special marker used. In contrast to Dietel et al., in the present study different DC subsets were analyzed. We characterized not only myeloid, but also plasmacytoid DCs (CD123+, CD304+) and different stages of maturation. Furthermore, different T cell subsets were investigated in our study: T helper cells, cytotoxic T cells, natural killer cells, and CD25+ as well as CD69+ activated T cells.

Immunostaining with antibodies against different chemokine receptors revealed a correlation between CCR6+ and CD8 cells. Also, a correlation between CCR4+ and proinflammatory T cells and mDCs and an inverse correlation between CCR4+ cells and Tregs were visible. This might support the idea that these CCRs have an important function in chemoattraction of proinflammatory \[[@B30]\] but obviously not anti-inflammatory cells in the course of atherogenesis.

Interestingly, in our study DCs and different subtypes of proinflammatory T cells positively correlated with the progression of atherosclerosis. Analyzing the frequency of DCs (CD83+, CD209+) in comparison with Tregs, a significant inverse correlation was observed. This is in agreement with the results of Dietel et al. \[[@B29]\] who also showed an inverse correlation. Assuming an anti-inflammatory function of Tregs \[[@B31]\], these observations of a concordant increase with proinflammatory cells and an inverse correlation with Tregs suggest DCs to function as an inductor of proinflammatory T cells and suppressor of Tregs in atherosclerosis.

Analyzing the distribution of Tregs in different plaque regions during plaque progression, we were able to show that Tregs are mainly present in the lipid core. Tregs present in unstable lesions seem to migrate into the lipid core and not to the same extent into the plaque shoulder regions where anti-inflammation would presumably be more important because these regions are the rupture-prone plaque regions.

Regarding the clinical data of the patients of the present study, one might notice that the percentage of male individuals is higher in the stable plaques group. Anyway, analyzing the cell numbers for men compared to women, there are no significant differences. There are no significant differences regarding cell numbers in carotid compared to femoral plaques. Interestingly, there is no difference in frequency of the examined immune cells considering cardiovascular risk factors or ischemic symptoms \[[@B13]\]. The reason for this difference might be the use of not only carotid but also femoral plaques for immunostaining in this study. Patients with peripheral arterial disease mainly suffer from chronic pain, but symptoms of acute vascular occlusion are rarely found.

Interestingly, there is an association of mDCs and Tregs with statin medication. Plaques of statin-treated patients showed a significantly lower number of DCs and a significantly higher number of Tregs. Even though not all studies demonstrated an anti-inflammatory effect of statins \[[@B32]\], our observations are in agreement with the majority of recent publications suggesting a plaque stabilizing effect of statin treatment \[[@B13], [@B33]\]. Regarding the different substances of statins, the dose-dependent effect of statin medication, or the effect of the duration of the statin treatment, we were not able to detect significant differences in the current study. This might be due to the size of the number of included patients.

In conclusion, the present study is one of the first showing a significantly lower number of Tregs in unstable atherosclerotic lesions compared to stable ones. This reduction in anti-inflammatory cells during atherogenesis might be an important reason for plaque destabilization. The increasing number of mDCs in the course of plaque progression, for which we were able to show a proinflammatory effect in the present study, might be the reason for a decrease in Tregs. This observation raises new questions about the interaction of DCs and Tregs which should be the point of interest in further studies.
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![Trichrome staining of atherosclerotic plaques enabling histological classification in stable or unstable lesions. Trichrome staining (20x) of a control vessel, a stable plaque with mainly fibrous tissue and a thick fibrous cap, and an unstable plaque with a large lipid core and/or a thin fibrous cap. Scheme of an atherosclerotic plaque demonstrating the different plaque regions is also shown: lipid core (LC), plaque shoulders (PS), fibrous cap (FC), media (M), and contralateral wall (CW).](MI2015-364710.001){#fig1}

![Emergence of myeloid DCs in atherosclerotic plaques. (a) Immunohistochemical staining of fascin+ mDCs of a control vessel and of the plaque shoulder regions of a stable and an unstable plaque (200x). The pie diagrams demonstrate the percentage of immunostained cells present in different plaque regions (LC---lipid core, PS---plaque shoulders, FC---fibrous cap, M---media, and CW---contralateral wall). (b) Mean DC number of control vessels (*n* = 12), stable (*n* = 14), and unstable (*n* = 15) plaques. Results are expressed as cells per 0.1 mm^2^. Values are presented as median (25--75% CI), ^\*^ *P* \< 0.05, ^\*\*^ *P* \< 0.01 (mDCs---myeloid DCs, pDCs---plasmacytoid DCs).](MI2015-364710.002){#fig2}

![T cell emergence in atherosclerotic lesions. (a) Immunohistochemical staining of proinflammatory CD4+ T helper cells of a control vessel and of the plaque shoulder regions of a stable and an unstable atherosclerotic plaque (200x). The pie diagrams demonstrate the percentage of immunostained cells present in each plaque region (LC---lipid core, PS---plaque shoulders, FC---fibrous cap, M---media, and CW---contralateral wall). (b) Mean T cell numbers of control vessels (*n* = 12), stable (*n* = 14), and unstable (*n* = 15) plaques. Results are expressed as cells per 0.1 mm^2^. Values are presented as median (25--75% CI). ^\*^ *P* \< 0.05, ^\*\*^ *P* \< 0.01.](MI2015-364710.003){#fig3}

![Emergence of Tregs in atherosclerotic lesions. (a) Immunohistochemical staining of Tregs of a control vessel without atherosclerosis and the plaque shoulder regions of a stable and an unstable atherosclerotic lesion (200x). The pie diagrams demonstrate the percentage of immunostained cells present in each plaque region (LC---lipid core, PS---plaque shoulders, FC---fibrous cap, M---media, and CW---contralateral wall). (b) Mean Treg number of control vessels (*n* = 12), stable (*n* = 14), and unstable (*n* = 15) plaques. Results are expressed as cells per 0.1 mm^2^. Values are presented as median (25--75% CI), ^\*^ *P* \< 0.05, ^\*\*^ *P* \< 0.01 (Tregs---regulatory T cells). Right lower corner: isotype control of a control vessel and a plaque.](MI2015-364710.004){#fig4}

![Emergence of activated cells in atherosclerotic lesions. (a) Immunohistochemical staining of activated CD25+ T cells of a control vessel without atherosclerosis and of the plaque shoulder regions of a stable and an unstable atherosclerotic lesion (200x). The pie diagrams demonstrate the percentage of immunostained cells present in each plaque region (LC---lipid core, PS---plaque shoulders, FC---fibrous cap, M---media, and CW---contralateral wall). (b) Mean CD25+ activated T cell, mean CD69+ activated T cell, and mean HLA-DR+ DC number of control vessels (*n* = 12), stable (*n* = 14), and unstable (*n* = 15) plaques. Results are expressed as cells per 0.1 mm^2^. Values are presented as median (25--75% CI), ^\*^ *P* \< 0.05, ^\*\*^ *P* \< 0.01.](MI2015-364710.005){#fig5}

![Inverse correlation between the median numbers of Tregs and proinflammatory cells in atherosclerotic plaques. The correlation analyses show the significant inverse correlation between the median number of Tregs and T helper cells (a), mature mDCs (b), and immature mDCs (c).](MI2015-364710.006){#fig6}

![Plaque stability and preoperative statin treatment. (a) Median lipid core ratio (LCR = lipid core area/plaque area × 100, (a)) as a plaque stability criteria, median number of fascin+ DCs/0.1 mm² (b), and FoxP3+ Tregs/0.1 mm² (c) of/in plaques of patients with (+) and without (−) preoperative statin medication.](MI2015-364710.007){#fig7}

###### 

Clinical data: cardiovascular risk factors and medications of the study groups.

                                     Group A             Group B             *P* value
  ---------------------------------- ------------------- ------------------- -----------
  Age (years)                        69.5 (57.8--78)     75 (72--77)         n.s.
  BMI (kg/m^2^)                      28.1 (25.3--29.7)   26.4 (24.5--29.1)   n.s.
  Gender, male (%)                   57                  87                  n.s.
  Ischemic symptoms (%)              64                  67                  n.s.
  Preoperative imaging:                                                       
   Degree of stenosis                80% (70--95%)       90% (80--95%)       n.s.
  Blood parameters:                                                           
   Leukocytes (Gpt/L)                9.5 (6.7--14.4)     8.1 (7--10.1)       n.s.
   CRP (mg/L)                        9.3 (1--35)         2.1 (1--32)         n.s.
   Creatinine (*μ*mol/L)             86 (66--157)        74 (60--133)        n.s.
  Morbidities:                                                                
   Hypertension (%)                  100                 93                  n.s.
   Hyperlipidemia (%)                100                 73                  n.s.
   Obesity (%) (BMI \> 30 kg/m^2^)   14                  20                  n.s.
   CHD (%)                           21                  53                  n.s.
   CKD (%) (GFR \< 50 mL/min)        29                  33                  n.s.
   Diabetes (%)                      36                  47                  n.s.
  Medication:                                                                 
   ASA (%)                           71                  60                  n.s.
   Beta blocker (%)                  43                  73                  n.s.
   ACE Inhibitor (%)                 43                  60                  n.s.
   Statins (%)                       92                  60                  n.s.

Group A: patients with stable, fibrous atherosclerotic lesions, group B: patients with unstable, lipid-rich atherosclerotic plaques. Values are presented as median and 25%--75% confidence interval or percentage.

^\*^ACE: angiotensin-converting enzyme; ASA: acetyl-salicylic acid; BMI: body mass index; CHD: coronary heart disease; CKD: chronic kidney disease; CRP: C-reactive protein; GFR: glomerular filtration rate; LDL: low-density lipoprotein.

###### 

Histological criteria for the determination of atherosclerotic plaques as "stable" or "unstable."

                            Stable plaque (SP)   Unstable plaque (UP)   *P* value                
  ------------------------- -------------------- ---------------------- ----------- ------------ -----------
  Fibrous cap (in *μ*m)     **267**              181--440               **96**      0--223       *0.02*
  LCR                       **0.21**             0.08--0.28             **0.64**    0.54--0.76   *\<0.001*
  Neovessels (/0.2 mm^2^)   **0**                0--0.3                 **3**       3--5         *\<0.001*

^\*^LCR: lipid core ratio; LCR: lipid core area/plaque area × 100.

###### 

Antibodies used for immunohistochemical analyses.

  Antibodies   Source            Dilution   Specificity
  ------------ ----------------- ---------- ---------------------------------------------------------------------------------------------------
  CD86         Milteyi Biotec    1 : 25     APCs
  CD68         Dako              1 : 50     Macrophages
  S-100        Dako              1 : 500    Glial Cells, ependyma, Schwann cells, mDCs
  Fascin       Dako              1 : 100    mDCs
  CD83         Serotec           1 : 40     Mature mDCs
  CD209        BD Pharmingen     1 : 100    Immature mDCs
  CD304        Miltenyi Biotec   1 : 100    pDCs
  CD123        Serotec           1 : 100    pDCs
  HLA-DR       Dako              1 : 25     APCs
  CD3          Miltenyi Biotec   1 : 100    T cells
  CD4          Dako              1 : 50     T helper cells
  CD8          Dako              1 : 200    Cytotoxic T cells
  CD161        Serotec           1 : 20     Natural killer cells
  CD25         Invitrogen        1 : 20     Activated B and T cells, regulatory T cells
  CD69         Ab cam            1 : 100    Activated B and T cells, regulatory T cells (early activation marker), macrophages, and platelets
  FoxP3        BioLegend         1 : 20     Regulatory T cells
  CD34         Dako              1 : 50     Endothelial cells
  CCR4         BioLegend         1 : 50     Chemokine receptor of DC, T cells, and B cells
  CCR-6        R&D               1 : 80     Chemokine receptor of immature DCs

^\*^APC: antigen presenting cell; mDCs: monocytoid dendritic cells; pDCs: plasmacytoid dendritic cells.

###### 

Frequency of pro- and anti-inflammatory cells in unstable and stable plaques.

  IHC marker              Control vessel (CV)   Stable plaque (SP)              Unstable plaque (UP)                                                    
  ----------------------- --------------------- -------------------- ---------- ---------------------- ----------- ---------- ------------- ----------- -----------
  APC/DC                                                                                                                                                 
   CD68                   **13.8**              5.0--19.8            **43.9**   27.0--74.4             *\<0.001*   **58.3**   25.2--98.2    *\<0.01*    n.s.
   Fascin                 **35.0**              24.1--46.9           **42.2**   20.0--55.8             n.s.        **67.2**   40.0--96.2    *0.01*      *0.03*
   S100                   **57.3**              6.4--108.8           **53.5**   25.3--73.4             n.s.        **87.0**   48.7--95.3    n.s.        *0.01*
   CD83                   **9.3**               0.0--36.1            **14.9**   5.7--49.5              n.s.        **87.2**   31.5--102.3   *0.004*     *0.003*
   CD209                  **14.3**              6.0--31.8            **17.5**   9.2--23.9              n.s.        **43.5**   23.7--70.6    *0.01*      *0.004*
   CD123                  **3.3**               0.1--16.1            **2.4**    0.8--7.9               n.s.        **4.0**    0.5--6.8      n.s.        n.s.
   CD304                  **13.3**              0.0--38.5            **2.5**    0.5--14.1              n.s.        **4.0**    2.7--14.5     n.s.        n.s.
  Functional APC marker                                                                                                                                  
   HLA-DR                 **32.0**              15.1--72.0           **49.1**   34.9--78.6             n.s.        **77.0**   48.4--119.6   *0.007*     *0.03*
  T cells                                                                                                                                                
   CD3                    **12.3**              4.5--31.4            **24.3**   7.6--37.8              n.s.        **55.8**   44.5--75.3    *0.002*     *\<0.001*
   CD4                    **9.0**               0.8--19.0            **5.5**    2.7--7.8               n.s.        **18.8**   6.5--29.0     n.s.        *0.008*
   CD8                    **3.5**               0.5--9.5             **5.3**    2.9--10.3              n.s.        **18.0**   10.3--22.2    *0.001*     *0.001*
   CD161                  **4.0**               0.0--28.0            **16.8**   6.2--22.2              n.s.        **25.3**   14.1--37.2    *0.02*      *0.03*
  Activated T cells                                                                                                                                      
   CD25                   **11.5**              0.5--23.0            **4.0**    1.2--13.3              n.s.        **26.3**   11.3--36.0    n.s.        *0.004*
   CD69                   **1.3**               0.75--2.0            **2.3**    0.17--3.17             n.s.        **3.8**    2.5--9.5      n.s.        *0.04*
  Tregs                                                                                                                                                  
   FoxP3                  **7.3**               3.8--43.8            **31.9**   16.3--49.8             *0.02*      **9.0**    2.7--24.6     n.s.        *0.002*
  Chemokine Receptors                                                                                                                                    
   CCR6                   **38.0**              11.5--50.0           **36.3**   16.5--57.0             n.s.        **75.0**   48.5--92.0    *0.004*     *0.007*
   CCR4                   **32.5**              24.0--43.5           **43.0**   13.2--61.0             n.s.        **89.3**   54.0--102.5   *\<0.001*   *0.003*

Values are presented as median and 25%--75% confidence interval or percentage.

^\*^APC: antigen presenting cell; CCR: chemokine receptor; Tregs: regulatory T cells; CV: control vessel; SP: stable plaque; UP: unstable plaque.

###### 

Correlation analyses of inflammatory cells, activation markers, and chemokine receptors.

  Correlation between     Correlation coefficient   *P* value   
  ----------------------- ------------------------- ----------- ---------
  Anti-inflamm. T cells   Proinflamm. cells                      
   FoxP3                   CD83                     −0.39       0.04
   FoxP3                   CD209                    −0.43       0.02
   FoxP3                   CD4                      −0.4        0.03
  Proinflamm. T cells     DCs                                    
   CD8                     Fascin                   0.55        0.002
   CD4                     Fascin                   0.66        \<0.001
   CD3                     Fascin                   0.41        0.03
   CD161                   Fascin                   0.61        \<0.001
   CD8                     CD209                    0.67        \<0.001
   CD4                     S100                     0.54        0.003
   CD3                     CD209                    0.49        0.008
   CD161                   CD83                     0.56        0.002
   CD161                   CD209                    0.42        0.02
   CD161                   S100                     0.44        0.02
  T cell activation       DC activation                          
   CD25                    HLA-DR                   0.67        \<0.001
  Chemokine receptor      Proinflammatory cells                  
   CCR4                    HLA-DR                   0.46        0.01
   CCR4                    CD3                      0.56        0.002
   CCR4                    S100                     0.45        0.02
   CCR4                    CD83                     0.43        0.02
   CCR4                    CD209                    0.39        0.04
   CCR4                    CD4                      0.45        0.02
   CCR4                    CD25                     0.48        0.01
   CCR4                    CD3                      0.56        0.002
  Chemokine receptor      Anti-inflamm. T cell                   
   CCR4                    FoxP3                    −0.38       0.04

[^1]: Academic Editor: Dianne Cooper
